2023
Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets
Warren R, Strober B, Silverberg J, Guttman E, Andres P, Felding J, Tutkunkardas D, Kjøller K, Sommer M, French L. Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets. Journal Of The European Academy Of Dermatology And Venereology 2023, 37: 711-720. PMID: 36478476, DOI: 10.1111/jdv.18812.Peer-Reviewed Original ResearchMeSH KeywordsDouble-Blind MethodFastingHumansPhosphodiesterase 4 InhibitorsProspective StudiesPsoriasisTabletsTreatment OutcomeConceptsPhase 1 trialPhase 2a trialSevere psoriasisAdverse eventsIR formulationPK propertiesWeek 16Psoriasis Area Severity Index (PASI) scorePlacebo-controlled trialSeverity Index scoreHigh-fat mealLow-fat mealPhosphodiesterase 4 inhibitorSimilar PK propertiesImmediate-release formulationGI disordersMR groupPlaceboFood effectPhase 2aIndex scorePsoriasisPharmacokinetic propertiesHealthy participantsMR formulation
2022
Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry
Ogdie A, Harrison R, McLean R, Lin T, Lebwohl M, Strober B, Zhuo J, Patel V, Mease P. Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. Journal Of The American Academy Of Dermatology 2022, 87: 1303-1311. PMID: 35987397, DOI: 10.1016/j.jaad.2022.07.060.Peer-Reviewed Original ResearchMeSH KeywordsArthritis, PsoriaticHumansProspective StudiesPsoriasisRegistriesSurveys and QuestionnairesConceptsPsoriasis Epidemiology Screening ToolBody mass indexProspective cohort studyPsoriasis RegistryCohort studyRheumatic Disease Comorbidity IndexOnset of PsAPatient-reported fatigueDevelopment of PsALogistic regression modelsComorbidity indexPsoriatic arthritisMass indexRisk model developmentArthritis riskPatientsScreening toolAlcohol usePSAUnique predictive modelsWork statusMisclassification biasCharacteristic curvePsoriasisRegistry
2017
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
Strober B, Karki C, Mason M, Guo N, Holmgren S, Greenberg J, Lebwohl M. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2017, 78: 323-332. PMID: 29051036, DOI: 10.1016/j.jaad.2017.10.012.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Inflammatory Agents, Non-SteroidalBiological ProductsBody Surface AreaComorbidityCost of IllnessCross-Sectional StudiesFatigueFemaleHumansInterleukin-12Interleukin-17Interleukin-23MaleMiddle AgedPainPatient Reported Outcome MeasuresProspective StudiesPsoriasisQuality of LifeRegistriesSeverity of Illness IndexThalidomideTumor Necrosis Factor-alphaUnited StatesConceptsCorrona Psoriasis RegistryPsoriasis RegistryDisease durationComparative safetyBody surface area involvementTumor necrosis factor inhibitorsIL-12/23 inhibitorsInterleukin-17A inhibitorInvestigator's Global AssessmentNecrosis factor inhibitorsSurface area involvementLonger disease durationCross-sectional studyLong-term safetyEfficacy of treatmentPsoriatic arthritis diagnosisQuality of lifeEfficacy of foodMultiple comorbiditiesRegistry cohortSystemic medicationsSystemic therapyFactor inhibitorsArea involvementBiologic treatment
2016
Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])
Strober B, Bissonnette R, Fiorentino D, Kimball A, Naldi L, Shear N, Goyal K, Fakharzadeh S, Calabro S, Langholff W, You Y, Galindo C, Lee S, Lebwohl M. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). Journal Of The American Academy Of Dermatology 2016, 74: 851-861.e4. PMID: 26853180, DOI: 10.1016/j.jaad.2015.12.017.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabAdultBiological ProductsConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleEtanerceptFemaleFollow-Up StudiesGlobal HealthHumansInfliximabLongitudinal StudiesMaleMiddle AgedOdds RatioPatient SatisfactionProspective StudiesPsoriasisQuality of LifeRegistriesSeverity of Illness IndexTime FactorsTreatment OutcomeUstekinumabConceptsPhysician Global Assessment scoreGlobal assessment scoreBody surface areaReal-world settingAssessment scoresPsoriasis Longitudinal AssessmentProportion of patientsTreatment of psoriasisEffectiveness of biologicsTreatment selection biasTumor necrosis factorBiologic agentsEfficacy dataTherapeutic responseTumor necrosisNecrosis factorObservational studyTreatment decisionsAnalysis of covarianceEtanerceptComparative effectivenessAdalimumabInfliximabLongitudinal assessmentLogistic regression
2012
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
Papp K, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. Journal Of Drugs In Dermatology 2012, 11: 1210-7. PMID: 23134986.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArthritis, PsoriaticBody Mass IndexBody Surface AreaCardiovascular DiseasesData Interpretation, StatisticalFemaleHumansImmunologic FactorsInfliximabMaleMiddle AgedObesityPhototherapyProduct Surveillance, PostmarketingProspective StudiesPsoriasisRegistriesUstekinumabConceptsDisease-based registryBiologic agentsObservational studyMajor adverse cardiovascular eventsConventional systemic treatmentsGeneral psoriasis populationPsoriasis Longitudinal AssessmentAdverse cardiovascular eventsOverweight/obeseLong-term observational studyBody surface areaPsoriasis populationCardiovascular eventsCause mortalityAdverse eventsPsoriatic arthritisRegistry studySystemic agentsSystemic therapySystemic treatmentMedication historyDisease characteristicsSerious infectionsMean durationEfficacy data
2006
A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis
Belsito D, Wilson D, Warshaw E, Fowler J, Ehrlich A, Anderson B, Strober B, Willetts J, Rutledge E. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. Journal Of The American Academy Of Dermatology 2006, 55: 40-46. PMID: 16781290, DOI: 10.1016/j.jaad.2006.03.025.Peer-Reviewed Original ResearchConceptsAllergic contact dermatitisNickel-induced allergic contact dermatitisTacrolimus ointmentAdverse eventsContact dermatitisSymptoms of ACDGlobal assessmentChronic allergic contact dermatitisPhysician global assessmentTacrolimus ointment 0.1Pruritus scoreClinical trialsPruritus reductionDay 8TacrolimusDermatitisInner aspectPatientsOintmentSignsTolerabilityArmSymptomsAgentsTrials
2005
Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study
Strober B, Siu K, Alexis A, Kim G, Washenik K, Sinha A, Shupack J. Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study. Journal Of The American Academy Of Dermatology 2005, 52: 1082-1084. PMID: 15928633, DOI: 10.1016/j.jaad.2005.03.039.Peer-Reviewed Original ResearchConceptsSevere alopecia areataAlopecia areataAlopecia totalisAlopecia universalisOpen-label pilot studyEfficacy of etanerceptOpen-label studyTNF-alpha inhibitorsPrimary outcome measureEnd of treatmentAlopecia ToolHair regrowthOutcome measuresEtanerceptHealthy adultsAreataContinuous treatmentPilot studySignificant regrowthTotalisTreatmentUniversalisSubjectsSeverityWeeks